Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | CRHR1 | P34998 | 9/20 | 0.34 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.33 |
| ▸ | CDK2 | P24941 | 1/20 | 0.33 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5843803 | 0.92 | CRHR1 (0.38) | POLBCRHR1CCNA2CDK2TLR7 | |
| SCHEMBL11748160 | 0.79 | DPP4 (0.43) | POLB | |
| SCHEMBL11751563 | 0.76 | PGK1 (0.46) | POLBCRHR1TLR7ATM | |
| SCHEMBL11677248 | 0.76 | ATM (0.34) | POLBCRHR1CCNA2CDK2TLR7 | |
| SCHEMBL11676299 | 0.75 | PDE4A (0.38) | CRHR1CCNA2CDK2TLR7ATM | |
| SCHEMBL11680185 | 0.75 | MEN1 (0.43) | CRHR1CCNA2CDK2TLR7ATM | |
| SCHEMBL9123060 | 0.74 | L3MBTL1 (0.45) | CRHR1TLR7 | |
| SCHEMBL8801677 | 0.73 | L3MBTL1 (0.41) | CRHR1TLR7ATM | |
| SCHEMBL6291599 | 0.71 | CRHR1 (0.51) | CRHR1 | |
| SCHEMBL7479132 | 0.71 | CRHR1 (0.36) | POLBCRHR1TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6869955-B2 | Tetrahydropteridines and pyridylpiperazines for treatment of neurological disorders | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-03-22 | — | — | US | disclosed |
| EP-1380298-A2 | Tetrahydropteridines and pyridylpiperazines for treatment of neurological disorders, anorexia, inflammation | Bristol-Myers Squibb Pharma Company (US) | 2004-01-14 | — | — | EP | disclosed |
| EP-0901374-B1 | TETRAHYDROPTERIDINES AND PYRIDYLPIPERAZINES FOR TREATMENT OF NEUROLOGICAL DISORDERS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2003-12-10 | — | — | EP | disclosed |
| US-20030064993-A1 | Tetrahydropteridines and pyridylpiperazines for treatment of neurological disorders | WILDE RICHARD GERALD (US) | 2003-04-03 | — | — | US | disclosed |
| US-6399609-B1 | CORTICOTROPIN RELEASING FACTOR (CRF) ANTAGONISTS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-06-04 | — | — | US | disclosed |
| US-6083948-A | TREATING ANXIETY, DEPRESSION, AND OTHER PSYCHIATRIC AND NEUROLOGICAL DISORDERS | DUPONT PHARMACEUTICALS COMPANY (US) | 2000-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030064993-A1 | Tetrahydropteridines and pyridylpiperazines for treatment of neurological disorders | CRH, CRHR1, CRHR2 | POLB 4512/4885CRHR1 2/4885CCNA2 2308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.